T1	Condition 18 26	pregnant
T2	Observation 30 43	breastfeeding
*	OR T1 T2
T3	Condition 61 66	STEMI
T4	Temporal 67 82	within 72 hours
T5	Qualifier 112 127;151 157	infarct related artery
T6	Qualifier 131 157	non-infarct related artery
*	OR T6 T5
T7	Procedure 99 108	treatment
T8	Scope 112 157	infarct related or non-infarct related artery
R1	Has_scope Arg1:T7 Arg2:T8	
R2	Has_temporal Arg1:T3 Arg2:T4	
R3	AND Arg1:T3 Arg2:T7	
T9	Condition 163 180	Cardiogenic shock
T10	Procedure 215 230	hospitalization
T11	Temporal 207 214	current
T12	Measurement 236 270	Left ventricular ejection fraction
T13	Value 271 284	less than 20%
R4	Has_value Arg1:T12 Arg2:T13	
T14	Drug 310 317	aspirin
T15	Drug 319 330	clopidogrel
T16	Drug 332 338	Plavix
T17	Drug 344 355	ticlopidine
T18	Drug 357 363	Ticlid
T19	Drug 366 373	heparin
T20	Drug 375 386	bivalirudin
T21	Observation 388 403	stainless steel
T22	Drug 408 422	contrast agent
T23	Condition 296 305	allergies
*	OR T14 T15 T16 T17 T18 T19 T20 T21 T22
T24	Scope 310 422	aspirin, clopidogrel (Plavix) and ticlopidine (Ticlid), heparin, bivalirudin, stainless steel, or contrast agent
R5	Has_scope Arg1:T23 Arg2:T24	
T25	Measurement 472 486	platelet count
T26	Value 487 513	less than 75,000 cells/mm3
T27	Value 517 547	greater than 700,000 cells/mm3
*	OR T26 T27
T28	Measurement 553 556	WBC
T29	Value 557 582	less than 3,000 cells/mm3
R6	Has_value Arg1:T28 Arg2:T29	
T30	Scope 487 547	less than 75,000 cells/mm3 or greater than 700,000 cells/mm3
R7	Has_scope Arg1:T25 Arg2:T30	
*	OR T25 T28
T31	Condition 597 622	chronic renal dysfunction
T32	Condition 588 593;605 622	Acute renal dysfunction
*	OR T31 T32
T33	Measurement 624 634	creatinine
T34	Value 635 657	greater than 2.5 mg/dl
T35	Value 661 680	less than 150µmol/L
*	OR T34 T35
T36	Scope 635 680	greater than 2.5 mg/dl or less than 150µmol/L
R8	Has_scope Arg1:T33 Arg2:T36	
T37	Context_Error 687 1045	Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials).
T38	Post-eligibility 687 1045	Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials).
T39	Context_Error 1050 1084	Prior participation in this study.
T40	Temporal 1090 1139	Within 30 days prior to the index study procedure
T41	Reference_point 1114 1139	the index study procedure
T42	Procedure 1178 1211	coronary interventional procedure
T43	Temporal 1169 1177	previous
R9	Has_temporal Arg1:T42 Arg2:T43	
T45	Condition 1279 1284	STEMI
T44	Condition 1300 1306	Stroke
T46	Condition 1310 1335	transient ischemic attack
R10	multi Arg1:T40 Arg2:T41	
R11	Has_temporal Arg1:T42 Arg2:T40	
T47	Negation 1261 1264	not
R12	Has_negation Arg1:T45 Arg2:T47	
T48	Temporal 1336 1361	within the prior 3 months
*	OR T46 T44
T49	Scope 1300 1335	Stroke or transient ischemic attack
R13	Has_temporal Arg1:T49 Arg2:T48	
T50	Condition 1375 1387	peptic ulcer
T51	Temporal 1368 1374	Active
T52	Condition 1391 1422	upper gastrointestinal bleeding
T53	Temporal 1423 1448	within the prior 3 months
T54	Scope 1375 1422	peptic ulcer or upper gastrointestinal bleeding
*	OR T52 T50
R14	Has_temporal Arg1:T54 Arg2:T51	
R15	Has_temporal Arg1:T54 Arg2:T53	
T55	Condition 1474 1480	sepsis
T56	Temporal 1467 1473	active
R16	Has_temporal Arg1:T55 Arg2:T56	
T57	Condition 1499 1532	left main coronary artery disease
T58	Qualifier 1487 1498	Unprotected
R17	Has_qualifier Arg1:T57 Arg2:T58	
T59	Measurement 1534 1542	stenosis
T60	Condition 1534 1542	stenosis
T61	Value 1543 1559	greater than 50%
R18	multi Arg1:T60 Arg2:T59	
R19	Has_value Arg1:T59 Arg2:T61	
R20	AND Arg1:T57 Arg2:T60	
T62	Subjective_judgement 1567 1596	In the investigator's opinion
T63	Measurement 1656 1671	life expectancy
T64	Observation 1656 1671	life expectancy
R21	multi Arg1:T64 Arg2:T63	
T65	Value 1675 1693	less than one year
R22	Has_value Arg1:T63 Arg2:T65	
T66	Post-eligibility 1567 1840	In the investigator's opinion, subject has a co-morbid condition(s) that could limit the life expectancy to less than one year, or limit the subject's ability to participate in the study or comply with follow-up requirements or impact the scientific integrity of the study.
T67	Condition 1899 1914	coronary lesion
T68	Measurement 1899 1914	coronary lesion
T69	Value 1918 1940	less than 50% stenosis
T70	Condition 1932 1940	stenosis
R23	multi Arg1:T69 Arg2:T70	
R24	multi Arg1:T67 Arg2:T68	
R25	Has_value Arg1:T68 Arg2:T69	
T71	Condition 1994 2002	thrombus
T72	Procedure 2018 2044	target vessel thrombectomy
T73	Condition 2047 2058	tortuousity
T74	Value 2060 2082	greater than 60 degree
T75	Measurement 2083 2088	angle
R26	Has_value Arg1:T75 Arg2:T74	
R27	Subsumes Arg1:T73 Arg2:T75	
T76	Procedure 2126 2155	stent delivery and deployment
T77	Qualifier 2104 2125	unsuitable for proper
T78	Subjective_judgement 2104 2125	unsuitable for proper
R28	Has_qualifier Arg1:T76 Arg2:T77	
R29	causal Arg1:T73 Arg2:T76	
T79	Condition 2164 2177	calcification
T80	Qualifier 2158 2163	heavy
R30	Has_qualifier Arg1:T79 Arg2:T80	
T81	Device 2228 2299	device other than percutaneous transluminal coronary angioplasty (PTCA)
T82	Procedure 2246 2299	percutaneous transluminal coronary angioplasty (PTCA)
R31	multi Arg1:T81 Arg2:T82	
T83	Negation 2235 2245	other than
R32	Has_negation Arg1:T82 Arg2:T83	
T84	Procedure 2309 2324	stent placement
T85	Temporal 2300 2324	prior to stent placement
T86	Reference_point 2309 2324	stent placement
R33	multi Arg1:T85 Arg2:T86	
R34	multi Arg1:T86 Arg2:T84	
T87	Procedure 2351 2383	directional coronary atherectomy
T88	Procedure 2385 2398	excimer laser
T89	Procedure 2400 2422	rotational atherectomy
*	OR T88 T89 T87
T90	Scope 2351 2422	directional coronary atherectomy, excimer laser, rotational atherectomy
R35	Subsumes Arg1:T84 Arg2:T90	
T91	Mood 2202 2210	requires
T92	Procedure 2211 2220	treatment
R36	AND Arg1:T92 Arg2:T81	
R37	Has_temporal Arg1:T92 Arg2:T85	
R38	Has_mood Arg1:T92 Arg2:T91	
T93	Condition 2188 2201	target lesion
R39	AND Arg1:T93 Arg2:T92	
T94	Device 2468 2488	saphenous vein graft
T95	Condition 2440 2446	lesion
T96	Qualifier 2455 2488	located in a saphenous vein graft
R40	multi Arg1:T96 Arg2:T94	
R41	Has_qualifier Arg1:T95 Arg2:T96	
T97	Qualifier 2515 2539	within the native vessel
T98	Grammar_Error 2571 2583	are eligible
T99	Qualifier 2544 2570	accessed through the graft
*	OR T97 T99
T100	Scope 2515 2570	within the native vessel but accessed through the graft
*	OR T96 T100
T101	Non-representable 2590 2780	The target vessel is in a "last remaining" epicardial vessel (e.g. greater than 2 non-target epicardial vessels and the bypass grafts to these territories [if present] are totally occluded).
